Amgen AMGN KYPROLIS — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's kyprolis — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's KYPROLIS — total revenues?
- Amgen (AMGN) reported KYPROLIS — total revenues of $330M in Q1 2026.
- How has Amgen's KYPROLIS — total revenues changed year-over-year?
- Amgen's KYPROLIS — total revenues increased by 1.9% year-over-year, from $324M to $330M.
- What is the long-term trend for Amgen's KYPROLIS — total revenues?
- Over 4 years (2021 to 2025), Amgen's KYPROLIS — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $1.11B to $1.41B.
- What does KYPROLIS — total revenues mean?
- The total revenue generated from the sales of the oncology drug Kyprolis.
- How do you interpret KYPROLIS — total revenues?
- An increase indicates growing market share or successful clinical adoption in the multiple myeloma space, while a decrease may signal increased competition from generics, biosimilars, or newer therapeutic classes.
- How does KYPROLIS — total revenues compare across companies?
- Comparable to revenue metrics for specialized oncology products or targeted therapies in the portfolios of large-cap biopharmaceutical peers.